Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer.
about
Neoadjuvant therapy for pancreas cancer: past lessons and future therapiesDoes finding early recurrence improve outcomes, and at what cost?Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain.Neoadjuvant chemotherapy in borderline resectable pancreatic cancer: A case report.Levels of CEA, CA153, CA199, CA724 and AFP in nipple discharge of breast cancer patients.CA19-9 Normalization During Pre-operative Treatment Predicts Longer Survival for Patients with Locally Progressed Pancreatic CancerRecent Advances in Pancreatic Cancer Surgery.The role of neoadjuvant therapy in pancreatic cancer: a review.Change in carbohydrate antigen 19-9 level as a prognostic marker of overall survival in locally advanced pancreatic cancer treated with concurrent chemoradiotherapy.Borderline resectable pancreatic cancer: conceptual evolution and current approach to image-based classification.Preoperative FOLFIRINOX for borderline resectable pancreatic cancer: Is radiation necessary in the modern era of chemotherapy?Does radiologic response correlate to pathologic response in patients undergoing neoadjuvant therapy for borderline resectable pancreatic malignancy?Serum CA 19-9 response to neoadjuvant therapy is associated with outcome in pancreatic adenocarcinoma.Surgical strategies and novel therapies for locally advanced pancreatic cancer.Neoadjuvant treatment for borderline and resectable pancreatic ductal adenocarcinoma.Survival impact of neoadjuvant gemcitabine plus S-1 chemotherapy for patients with borderline resectable pancreatic carcinoma with arterial contact.Neoadjuvant Therapy of Pancreatic Cancer: Definitions and Benefits.Serum CA242, CA199, CA125, CEA, and TSGF are Biomarkers for the Efficacy and Prognosis of Cryoablation in Pancreatic Cancer Patients.Neoadjuvant treatment of pancreatic adenocarcinoma: a systematic review and meta-analysis of 5520 patients.Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival.One- vs. Three-Fraction Pancreatic Stereotactic Body Radiation Therapy for Pancreatic Carcinoma: Single Institution Retrospective Review.Contemporary Management of Localized Resectable Pancreatic Cancer.How to treat borderline resectable pancreatic cancer: current challenges and future directions.Selecting patients for resection after primary chemotherapy for non-metastatic pancreatic adenocarcinoma.Imaging-based biomarkers: Changes in the tumor interface of pancreatic ductal adenocarcinoma on computed tomography scans indicate response to cytotoxic therapy.Serum carbohydrate antigen 19-9 in pancreatic adenocarcinoma: a mini review for surgeons.Prognostic impact of normalization of serum tumor markers following neoadjuvant chemotherapy in patients with borderline resectable pancreatic carcinoma with arterial contact.Treatment of borderline resectable pancreatic cancer.Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience.Downstaging in Stage IV Pancreatic Cancer: A New Population Eligible for Surgery?Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer.Prognostic Impact of Presurgical CA19-9 Level in Pancreatic Adenocarcinoma: A Pooled AnalysisCurrent Standards and Recent Advances in Biomarkers of Major Endocrine TumorsOptimal resection area for superior mesenteric artery nerve plexuses after neoadjuvant chemoradiotherapy for locally advanced pancreatic carcinoma
P2860
Q27004292-C684F78B-7BAB-42FF-9A91-622B71ED067CQ30249096-0FD28F67-3029-4994-87EF-BD464202206BQ33665450-776B28CC-5B60-4C91-9152-1BF3F3498165Q33750803-772052C5-8DF0-4AC3-97FE-94879A0704D7Q36492863-2D59159E-2A26-4C9C-9BE7-A575DE5E40BEQ37033444-B29E6ABC-056B-43BC-BE11-51C819BB6BF6Q38602630-F5A3A5C6-B2D7-4113-8176-D5C8C63916CDQ38734981-C6AB3ABA-C2A1-4ECF-B167-95D60EF5AEC8Q38801235-A781CB7C-B56C-4DA2-A006-8CC8F1E20FA7Q38838295-918324C3-FFAF-4B11-8015-439F2A9C16D3Q38905077-A9468A18-ABA1-47AD-BE58-3F6596E242E9Q39010876-2F75E6E5-243F-40E6-BBE1-F4324E59A098Q39148761-BB8C417F-0798-4033-9111-C60E072EB9E4Q39312912-265F56A7-B626-4D87-80C8-2A012947DCEDQ39371358-97981A09-3867-4C36-B463-94720500C2BDQ40461118-2A18794B-7B24-4BDB-AE64-5229E296BDAEQ41573034-914DBB68-C9B0-43FA-8AE1-B395BAC94EE1Q41715410-2CC292F8-9BA6-46B1-B9D6-E3BDBA5645EFQ42374126-707E9F56-0B9C-4A7D-87D1-4508C5550B6EQ44993391-82B3DA26-76BD-445B-BE4F-29E87457B735Q46390454-31F24C23-EB4D-44B0-9A26-4E65CBE9FB30Q47716584-55339F2F-4DDC-4E11-85DA-4254FEBC3EACQ47728528-F8030873-CFF7-45DA-A959-7D79FDFE4F2FQ47926291-BC7F8C27-50AC-4028-8094-7A77EE71940BQ48165156-D615B94E-0B71-4247-BB38-ADEC312128BAQ48248436-FB5C31BE-766F-40AC-A69C-1DBA6E4A5385Q50673073-79D84969-ECFB-4657-BDDC-A98D73A822B1Q51196995-1529AB54-30D4-42AF-BDBC-9671ACC50BDBQ51751748-A0FA9494-B06A-40DF-ACF5-68D7D9866A4BQ53286113-0CC75BDA-EA33-4F39-AE2D-45886755979EQ55634822-0F340CF0-1855-466C-9161-42D4AAD2D5A2Q57156597-B9D457E4-21D4-483B-9F1B-E75CA7DDFFB7Q57158952-26098B20-833B-468E-8780-1894DB2A053FQ58802147-26D21999-0958-4145-AD7D-3ABB134B8228
P2860
Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer.
description
2013 nî lūn-bûn
@nan
2013 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Serum carbohydrate antigen 19- ...... resectable pancreatic cancer.
@ast
Serum carbohydrate antigen 19- ...... resectable pancreatic cancer.
@en
Serum carbohydrate antigen 19- ...... resectable pancreatic cancer.
@nl
type
label
Serum carbohydrate antigen 19- ...... resectable pancreatic cancer.
@ast
Serum carbohydrate antigen 19- ...... resectable pancreatic cancer.
@en
Serum carbohydrate antigen 19- ...... resectable pancreatic cancer.
@nl
prefLabel
Serum carbohydrate antigen 19- ...... resectable pancreatic cancer.
@ast
Serum carbohydrate antigen 19- ...... resectable pancreatic cancer.
@en
Serum carbohydrate antigen 19- ...... resectable pancreatic cancer.
@nl
P2093
P2860
P356
P1476
Serum carbohydrate antigen 19- ...... resectable pancreatic cancer.
@en
P2093
Aparna Balachandran
Ching-Wei D Tzeng
Christopher H Crane
Gauri R Varadhachary
Huamin Wang
Jason B Fleming
Jeffrey E Lee
Matthew H G Katz
Mediha Ahmad
Peter W T Pisters
P2860
P304
P356
10.1111/HPB.12154
P577
2013-08-29T00:00:00Z